Log in
Enquire now

List of Jiangsu Hengrui Medicine patents

List of Jiangsu Hengrui Medicine patents
List of Theragenics Corporation patents
List of PhotoThera patents
List of University of Houston System patents
Companies in the Risk assessment industry
List of pesticide, fertilizer, and other agricultural chemical manufacturing patents
Patents where
Current Assignee
Name
is
‌
Jiangsu Hengrui Medicine
Name
Description
Patent Applicant
Current Assignee
Inventor
Patent Jurisdiction
Patent Number
Date of Patent
‌
US Patent 10150770 Crystal form of bisulfate of JAK inhibitor and preparation method therefor

Patent 10150770 was granted and assigned to Jiangsu Hengrui Medicine on December, 2018 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
10150770
December 11, 2018
‌
US Patent 9422300 Bisulfate of janus kinase (JAK) inhibitor and preparation method therefor

Patent 9422300 was granted and assigned to Jiangsu Hengrui Medicine on August, 2016 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
9422300
August 23, 2016
‌
US Patent 11304945 Pharmaceutical composition and method for preparing same

Patent 11304945 was granted and assigned to Jiangsu Hengrui Medicine on April, 2022 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
11304945
April 19, 2022
‌
US Patent 9951077 Aminopyridazinone compounds as protein kinase inhibitors

Patent 9951077 was granted and assigned to Jiangsu Hengrui Medicine on April, 2018 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
9951077
April 24, 2018
‌
US Patent 10144737 Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors

Patent 10144737 was granted and assigned to Jiangsu Hengrui Medicine on December, 2018 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
10144737
December 4, 2018
‌
US Patent 11407734 Preparation method for tyrosine kinase inhibitor and intermediate thereof

Patent 11407734 was granted and assigned to Jiangsu Hengrui Medicine on August, 2022 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
11407734
August 9, 2022
‌
US Patent 10301344 L-proline complex of sodium-glucose cotransporter 2 inhibitor, monohydrate and crystal form thereof

Patent 10301344 was granted and assigned to Jiangsu Hengrui Medicine on May, 2019 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
10301344
May 28, 2019
‌
US Patent 11000518 Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer

Patent 11000518 was granted and assigned to Jiangsu Hengrui Medicine on May, 2021 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
11000518
May 11, 2021
‌
US Patent 10786507 Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof

Patent 10786507 was granted and assigned to Jiangsu Hengrui Medicine on September, 2020 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
10786507
September 29, 2020
‌
US Patent 10160759 Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor

Patent 10160759 was granted and assigned to Jiangsu Hengrui Medicine on December, 2018 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
10160759
December 25, 2018
‌
US Patent 11059810 Pharmaceutically acceptable salt as renal outer medullary potassium channel inhibitor

Patent 11059810 was granted and assigned to Jiangsu Hengrui Medicine on July, 2021 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
11059810
July 13, 2021
‌
US Patent 11180505 Crystal form of PARP-1 inhibitor and preparation method therefor

Patent 11180505 was granted and assigned to Jiangsu Hengrui Medicine on November, 2021 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
11180505
November 23, 2021
‌
US Patent 10358424 Sodium salt of uric acid transporter inhibitor and crystalline form thereof

Patent 10358424 was granted and assigned to Jiangsu Hengrui Medicine on July, 2019 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
10358424
July 23, 2019
‌
US Patent 10966964 Method for preparing pharmaceutical composition comprising pyrrolo-fused six-membered heterocyclic compound

Patent 10966964 was granted and assigned to Jiangsu Hengrui Medicine on April, 2021 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
10966964
April 6, 2021
‌
US Patent 10973807 Pharmaceutical composition comprising pyrrolo-fused six-membered heterocyclic compound

Patent 10973807 was granted and assigned to Jiangsu Hengrui Medicine on April, 2021 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
10973807
April 13, 2021
‌
US Patent 10323037 Aminopyridazinone compounds as protein kinase inhibitors

Patent 10323037 was granted and assigned to Jiangsu Hengrui Medicine on June, 2019 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
10323037
June 18, 2019
‌
US Patent 11014914 Opioid receptor (MOR) agonist salt, fumarate salt crystal form I thereof and preparation method thereof

Patent 11014914 was granted and assigned to Jiangsu Hengrui Medicine on May, 2021 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
11014914
May 25, 2021
‌
US Patent 10196361 Sodium salt of uric acid transporter inhibitor and crystalline form thereof

Patent 10196361 was granted and assigned to Jiangsu Hengrui Medicine on February, 2019 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
10196361
February 5, 2019
‌
US Patent 11014888 Crystalline form of alkynyl pyridine prolyl hydroxylase inhibitor and method for preparing same

Patent 11014888 was granted and assigned to Jiangsu Hengrui Medicine on May, 2021 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
11014888
May 25, 2021
‌
US Patent 11155537 Crystal of benzofuran derivative free base and preparation method

Patent 11155537 was granted and assigned to Jiangsu Hengrui Medicine on October, 2021 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
11155537
October 26, 2021
‌
US Patent 11306085 Method for preparing pyrimidone heteroaryl derivative and intermediate of pyrimidone heteroaryl derivative

Patent 11306085 was granted and assigned to Jiangsu Hengrui Medicine on April, 2022 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
11306085
April 19, 2022
‌
US Patent 10709699 Pyridone derivative pharmaceutical composition and preparation method thereof

Patent 10709699 was granted and assigned to Jiangsu Hengrui Medicine on July, 2020 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
10709699
July 14, 2020
‌
US Patent 10030018 Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor

Patent 10030018 was granted and assigned to Jiangsu Hengrui Medicine on July, 2018 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
10030018
July 24, 2018
‌
US Patent 11241378 Pharmaceutical JAK kinase inhibitor and diethylene glycol composition for topical administration and preparation method therefor

Patent 11241378 was granted and assigned to Jiangsu Hengrui Medicine on February, 2022 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
11241378
February 8, 2022
‌
US Patent 9283189 Sustained-release preparation of ivabradine or pharmaceutically acceptable salts thereof

Patent 9283189 was granted and assigned to Jiangsu Hengrui Medicine on March, 2016 by the United States Patent and Trademark Office.

‌
Jiangsu Hengrui Medicine
United States Patent and Trademark Office
United States Patent and Trademark Office
9283189
March 15, 2016
Results per page:
53 results
0 selected
53 results
0 selected
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us